Results 11 to 20 of about 8,373 (204)

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

Hemato, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +3 more
doaj   +2 more sources

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. [PDF]

Blood Cancer J, 2018
AbstractImmunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea.
Gertz MA.
europepmc   +5 more sources

Daratumumab for Immunoglobulin Light Chain Amyloidosis [PDF]

Oncology & Haematology, 2021
Foteini Theodorakakou, Meletios Α. Dimopoulos, Efstathios Kastritis   +2 more
openalex   +3 more sources

Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study. [PDF]

Sci Rep, 2022
Palmer C, Truong VT, Slivnick JA, Wolking S, Coleman P, Mazur W, Zareba KM.   +6 more
europepmc   +3 more sources

Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation. [PDF]

Curr Oncol
Garami G, Obajed Al-Ali O, Virga I, Gulyás A, Bedekovics J, Tornai I, Illés Á, Magyari F.   +7 more
europepmc   +3 more sources

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. [PDF]

Circ Heart Fail, 2022
Maurer MS, Dunnmon P, Fontana M, Quarta CC, Prasad K, Witteles RM, Rapezzi C, Signorovitch J, Lousada I, Merlini G.   +9 more
europepmc   +2 more sources

Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment. [PDF]

J Natl Compr Canc Netw, 2023
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion, making a delay in diagnosis common, which contributes to the high early mortality seen in this disease.
Zanwar S, Gertz MA, Muchtar E.
europepmc   +3 more sources

Immunoglobulin light chain amyloidosis [PDF]

memo - Magazine of European Medical Oncology, 2021
SummaryImmunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains. The monoclonal light chain paraprotein originates from a small clonal B‑cell or a clonal plasma cell population.
Hermine Agis, Maria T. Krauth
openaire   +1 more source

Treatment of Immunoglobulin Light Chain Amyloidosis [PDF]

Mayo Clinic Proceedings, 2015
Angela Dispenzieri, Francis K. Buadi, Shaji Kumar, Craig B. Reeder, Tamur Sher, Martha Q. Lacy, Robert A. Kyle, Joseph Mıkhael, Vivek Roy, Nelson Leung, Martha Grogan, Prashant Kapoor, John A. Lust, David Dingli, Ronald S. Go, Yi L. Hwa, Suzanne R. Hayman, Rafaël Fonseca, Sikander Ailawadhi, P. Leif Bergsagel, A.A. Chanan‐Khan, S. Vincent Rajkumar, Stephen J. Russell, Keith Stewart, Steven R. Zeldenrust, Morie A. Gertz   +25 more
openalex   +2 more sources

Systemic immunoglobulin light chain amyloidosis [PDF]

Nature Reviews Disease Primers, 2018
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by the conversion of immunoglobulin light chains from their soluble functional states into highly organized amyloid fibrillar aggregates that lead to organ dysfunction.
Merlini G., Dispenzieri A., Sanchorawala V., Schonland S. O., Palladini G., Hawkins P. N., Gertz M. A.   +6 more
openaire   +6 more sources